Your session is about to expire
← Back to Search
Paclitaxel for Ovarian Cancer (VELIA Trial)
VELIA Trial Summary
This trial found that adding veliparib to standard platinum-based chemotherapy and continuing it as maintenance therapy did not prolong PFS in patients with advanced BRCA-mutated ovarian cancer.
- Ovarian Cancer
- Ovarian Neoplasms
VELIA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVELIA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729VELIA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many willing participants are needed for this experiment?
"Presently, this trial is not seeking new patients. The study was first made public on 6/29/2015 and was most recently edited on 5/26/2022. However, there are 665 other clinical trials for patients with ovary cancer and 1243 trials for Paclitaxel that are actively recruiting."
In how many different medical facilities is this test being administered currently?
"This trial has 100 total openings with centres including William Beaumont Hospital /ID# 139550 in Royal Oak, Univ Hosp Cleveland /ID# 139615 in Cleveland, and Mmcorc /Id# 139534 in Saint Louis Park, in addition to other research facilities."
What are the key goals of this experiment?
"The primary focus of this trial is to explore the impacts of the medication on Progression-Free Survival (PFS) in the Intention-to-treat Population over a period of 28 months. Additionally, researchers will also be secondary outcomes including Change From Baseline in Disease Related Symptom (DRS) Score in the HRD Population and Overall Survival (OS)."
Share this study with friends
Copy Link
Messenger